Natera (NTRA) is trading higher as investors digest a fresh legal win that boosts the company’s intellectual-property leverage in minimal residual disease (MRD) testing. A U.S. District Court in Delaware ordered a 30% ongoing royalty payable to Natera on certain post-injunction revenues from infringing MRD-related product sales by ArcherDx and Invitae, providing a clearer path to future cash flows tied to ongoing sales that qualify under limited exceptions to an existing injunction. (investor.natera.com)

Natera said the decision was issued on April 6, 2026, and that it sets an ongoing 30% royalty on post-injunction revenues for infringing MRD-related sales falling within the injunction’s exceptions (the injunction was issued November 21, 2023). The court also left intact the previously awarded effective 20.5% royalty on pre-injunction revenues and maintained the jury’s findings on patent validity and direct infringement for non-MRD products. (investor.natera.com)

The market is treating the ruling as a strengthening of Natera’s MRD moat because it pairs confirmation of patent validity with a specific ongoing royalty framework that can persist beyond one-time damages. Even without immediate quarter-by-quarter dollar guidance, the combination of enforceable IP and an ongoing royalty rate can improve perceived durability of MRD economics and negotiating leverage in future licensing and competitive disputes. (news.bloomberglaw.com)

Next focus areas are whether the parties pursue additional post-trial steps or appeals and how quickly the royalty mechanism translates into recognized revenue or cash receipts. Investors will also watch for any changes in competitive behavior in MRD testing and whether the legal outcome influences broader adoption or commercial partnerships tied to Natera’s Signatera franchise. (streetinsider.com)